HOME >> MEDICINE >> NEWS
2005 Potamkin Prize goes to neurologists for research in early detection of Alzheimer's disease

ST. PAUL, Minn. The American Academy of Neurology (AAN) will award the 2005 Potamkin Prize for Research in Pick's, Alzheimer's and Related Diseases to John C. Morris, MD, and Ronald C. Petersen, PhD, MD. The $100,000 Potamkin Prize will be awarded April 12 at the AAN Annual Meeting in Miami Beach, Fla.

Often called the "Nobel Prize of Neurology," the Potamkin Prize honors and rewards researchers for their work in helping advance the understanding of Alzheimer's disease and related disorders.

Morris is the Friedman Distinguished Professor of Neurology at Washington University School of Medicine in St. Louis, Mo., and director of the Alzheimer's Disease Research Center at Washington University.

Petersen is a professor of neurology at the Mayo Clinic College of Medicine in Rochester, Minn., and director of the Mayo Alzheimer's Disease Research Center.

Morris' research has focused on early stage Alzheimer's disease. "Intense interest in prodromal stages of Alzheimer's disease has prompted consideration of early detection methods," he said. "The Washington University Alzheimer's Disease Research Center approach incorporates informant observations with patient evaluations and results in the accurate identification of the earliest symptomatic stage of the disease. Current efforts focus on detection of preclinical Alzheimer's, prior to the onset of symptoms, using imaging modalities and assays of biological fluids."

John H. Growdon, MD, of Harvard University, who chaired the committee that selected the Prize recipients, said, "Dr. Morris' research has sharpened the boundary between truly healthy brain aging and incipient Alzheimer's disease. After establishing sensitive methods to distinguish Alzheimer's, he went on to show that amyloid plaques histologically signal the onset of AD years and possibly decades before clinical signs of dementia emerge. His findings point to a pre-clinical stage of AD that is an ideal target for potentia
'"/>

Contact: Marilee Reu
mreu@aan.com
651-695-2789
American Academy of Neurology
6-Apr-2005


Page: 1 2

Related medicine news :

1. Richard Mayeux awarded AAN Potamkin Prize for Alzheimers research
2. Greenberg Prize awarded to Dr. Joseph G. Hayes
3. TWAS, illycaff announce Trieste Science Prize winners 2007
4. New research says winning a Nobel Prize adds nearly two years to your lifespan
5. Brain cell and face perception research wins Eppendorf/Science Prize
6. Albert Szent-Gyrgyi Prize for Progress in Cancer Research to Harvards Harold F. Dvorak, M.D.
7. Floyd E. Bloom wins 2005 Sarnat Prize in Mental Health
8. Researchers win Nobel Medicine Prize for discovering cause of ulcers
9. Leading genomic technology expert to present Dickson Prize Lecture at Pitt
10. University of Maryland scientist wins 2005 Kettering Prize
11. 1 of 2 pediatric kidney disease research centers in world established

Post Your Comments:
(Date:5/20/2013)... Medicare Part D seniors in plans with preferred ... access to pharmacies and other benefits, according to a ... the Pharmaceutical Care Management Association (PCMA). More than 40% ... in plans with preferred networks. , “Seniors like the ... with preferred pharmacy networks,” said PCMA President and CEO ...
(Date:5/20/2013)... A new Benefits of Pharmacy Home Delivery report ... MedEx Pack announced. The new report offers ... order to provide useful details for those who are contemplating ... MedEx Direct owner and pharmacist said, “One of the biggest ... like the MedEx Pack, patients can receive their own pre-filled ...
(Date:5/20/2013)... new report suggests that improved health care and significant ... up the age-old relationship between physicians and drug company ... unnecessary prescription drugs. , This system, which has been ... by keeping them up to date on new medications, ... get patients started on the newest drugs, as well ...
(Date:5/20/2013)... GA (PRWEB) May 20, 2013 ... nominations for this year’s prestigious Information Security Executive® ... , Awards include the Information Security Executive® ... which recognize executives who have made a positive ... protection, regulatory compliance, privacy and information security; and ...
(Date:5/20/2013)... 20, 2013 Selexis SA, a serial ... and cell line development for scale-up and manufacturing of ... will present data on the Company’s core technology at ... Conference, May 20 - 23 at the Hyatt Regency ... co-founder and scientific advisory board member, Nicolas Mermod, PhD, ...
Breaking Medicine News(10 mins):Health News:Survey: 85% of Part D Seniors in Preferred Pharmacy Plans are Satisfied With Costs, Pharmacy Choices 2Health News:Benefits of Pharmacy Home Delivery Report Published by MedEx Direct 2Health News:Breakup of physician, drug company relationship could improve health care, cut cost 2Health News:Breakup of physician, drug company relationship could improve health care, cut cost 3Health News:T.E.N. Announces Call for Nominations for the ISE® Northeast Awards 2013 2Health News:T.E.N. Announces Call for Nominations for the ISE® Northeast Awards 2013 3Health News:Selexis SA to Present Technology Platform Data at Cell Line Development & Engineering 2Health News:Selexis SA to Present Technology Platform Data at Cell Line Development & Engineering 3
(Date:5/20/2013)... , May 20, 2013  AbbVie (NYSE: ... of a Phase 3 clinical study called SONAR ... the effects of the investigational compound atrasentan - when ... kidney disease in patients with stage 2 to ... diabetes.  SONAR is a large, multinational, double-blind, placebo-controlled ...
(Date:5/19/2013)... May 20, 2013  Whole-cell pertussis vaccines were more ... during a large recent outbreak, according to a new ... pertussis vaccines, also called DTwP, were available from the ... that ultimately led to the development of acellular pertussis ... 1990s, the United States had ...
(Date:5/18/2013)... , May 18, 2013 Faruqi ... firm, is investigating potential securities fraud at AVEO ... (Logo: http://photos.prnewswire.com/prnh/20120119/MM38856LOGO ) ... and its executives violated federal securities laws by ... Company,s Phase III drug trials for Tivopath (tivozanib) ...
Breaking Medicine Technology:AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 2AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 3AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 4AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 5AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 6Study Shows Whole-Cell Vaccine was More Effective than Acellular Vaccine During California Pertussis Outbreak 2Study Shows Whole-Cell Vaccine was More Effective than Acellular Vaccine During California Pertussis Outbreak 3Study Shows Whole-Cell Vaccine was More Effective than Acellular Vaccine During California Pertussis Outbreak 4Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In AVEO Pharmaceuticals, Inc. To Contact The Firm 2
Cached News: